The South & Central America myopia treatment market was valued at US$ 458.52 million in 2022 and is expected to reach US$ 676.01 million by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030.
The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia.
The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients.
Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
The myopia treatment market in Brazil has witnessed significant growth due to the escalating prevalence of myopia across the country. The spread of myopia in Brazil can be attributed to various factors. Urbanization and changing lifestyles have led to increased near-work activities, such as prolonged hours spent on digital devices and reading, contributing to the development and progression of myopia. Additionally, limited outdoor activities and reduced exposure to natural light among children and adults have been linked to a higher incidence of myopia.
Rising Availability of Advanced Technologies for Treating the Targeted Myopia Fuels South & Central America Myopia Treatment Market
The rising availability of advanced technologies for treating targeted myopia is a significant opportunity for the myopia treatment market. Advances in technologies such as laser-assisted in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lenses (ICL) have made it possible to correct myopia more effectively and with fewer complications. Various ground-breaking data were also presented during the congress; over 30 abstracts backed by Johnson & Johnson Vision have been approved for presentation. Surgeons can apply the innovative SILK (i.e., Smooth Incision Lenticule Keratomileusis) treatment to treat myopic patients who have astigmatism or do not utilize the ELITATM Platform.The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia.
The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients.
Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
South & Central America Myopia Treatment Market Overview
South & Central America includes Argentina, Brazil, and the Rest of South & Central America. The myopia treatment market in the region is expected to have several growth opportunities. The rise in the development of the medical industry in Brazil is likely to create significant growth opportunities for market growth. Similarly, Argentina's growing medical device industry is also expected to offer growth opportunities for the myopia treatment market.The myopia treatment market in Brazil has witnessed significant growth due to the escalating prevalence of myopia across the country. The spread of myopia in Brazil can be attributed to various factors. Urbanization and changing lifestyles have led to increased near-work activities, such as prolonged hours spent on digital devices and reading, contributing to the development and progression of myopia. Additionally, limited outdoor activities and reduced exposure to natural light among children and adults have been linked to a higher incidence of myopia.
South & Central America Myopia Treatment Market Segmentation
The South & Central America myopia treatment market is categorized into type, treatment, age group, end user, and country.- Based on type, the South & Central America myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest South & Central America myopia treatment market share in 2022.
- In terms of treatment, the South & Central America myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest South & Central America myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
- By age group, the South & Central America myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger South & Central America myopia treatment market share in 2022.
- Based on end user, the South & Central America myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest South & Central America myopia treatment market share in 2022.
- Based on country, the South & Central America myopia treatment market is categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America myopia treatment market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. South & Central America Myopia Treatment Market Landscape
5. South & Central America Myopia Treatment Market - Key Market Dynamics
7. South & Central America Myopia Treatment Market Analysis - by Type
8. South & Central America Myopia Treatment Market Analysis - by Treatment
9. South & Central America Myopia Treatment Market Analysis - by Age Group
10. South & Central America Myopia Treatment Market Analysis - by End User
11. South & Central America Myopia Treatment Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Bausch Health Companies Inc
- Alcon AG
- CooperVision Inc
- Johnson & Johnson Vision Care Inc
- Nidek Co Ltd
- Carl Zeiss AG
